menu
    • menu

    Company profile for GlycoNex

    NEW Drugs in Dev: 4
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GlycoNex Inc. is a pioneering Taiwanese biotechnology company. Through a collaboration with the Biomembrane Institute (TBI) and Dr. Sen-itiroh Hakomori in the US, GlycoNex became a leader in developing cancer therapies. The company combines advanced "glycosphingolipid antigen" and "human monoclonal antibody (mAb) technologies" to create innovative cancer drugs. By integrating these technologies, GlycoNex is at the forefront of...
    GlycoNex Inc. is a pioneering Taiwanese biotechnology company. Through a collaboration with the Biomembrane Institute (TBI) and Dr. Sen-itiroh Hakomori in the US, GlycoNex became a leader in developing cancer therapies. The company combines advanced "glycosphingolipid antigen" and "human monoclonal antibody (mAb) technologies" to create innovative cancer drugs. By integrating these technologies, GlycoNex is at the forefront of developing targeted treatments that aim to improve patient outcomes in oncology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GlycoNexTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    8F., No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.glyconex.com.tw/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Glyconex Inks CDMO Deal With Change Cure For Hmgb1 Antibody
    Glyconex Inks CDMO Deal With Change Cure For Hmgb1 Antibody

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/glyconex-signs-cdmo-service-agreement-with-change-cure-to-advance-hmgb1-targeted-antibody-program-302631535.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    GlycoNex and Hokkaido University Hospital Launch Study
    GlycoNex and Hokkaido University Hospital Launch Study

    24 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/glyconex-and-hokkaido-university-hospital-launch-study-to-advance-glycan-directed-adc-development-in-gastric-cancer-302623320.html

    PR NEWSWIRE
    24 Nov 2025
    Share Share
    GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8
    GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8

    29 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/glyconex-announces-last-patient-dosed-in-phase-3-trial-of-spd8-a-denosumab-biosimilar-for-osteoporosis-302597115.html

    PR NEWSWIRE
    29 Oct 2025
    Share Share
    Glyconex Abstract On GNX1021 ADC Accepted For AACR-NCI-EORTC 2025
    Glyconex Abstract On GNX1021 ADC Accepted For AACR-NCI-EORTC 2025

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/glyconex-abstract-on-glycan-directed-adc-gnx1021-accepted-for-presentation-at-aacr-nci-eortc-2025-302587717.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    GlycoNex Publish Preclinical Study on GNX1021 for Gastric Cancer
    GlycoNex Publish Preclinical Study on GNX1021 for Gastric Cancer

    12 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/glyconex-announces-publication-of-preclinical-study-on-gnx1021-a-novel-glycan-targeted-adc-for-gastric-cancer-302479096.html

    PR NEWSWIRE
    12 Jun 2025
    Share Share
    GlycoNex Publishes Research on Pro-Antibody GNX201 in Journal
    GlycoNex Publishes Research on Pro-Antibody GNX201 in Journal

    27 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/glyconex-announces-publication-of-research-involving-pro-antibody-gnx201-in-the-international-journal-of-biological-macromolecules-302465373.html

    PR NEWSWIRE
    27 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search